Back to results
US 2022/0106288 A1Published application
Novel sulfoneurea compounds
AssigneeInflazome Limited
InventorsAngus MACLEOD, Jonathan SHANNON, Stephen THOM, Jokin CARRILLO ARREGUI, Thomas ALANINE
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of formula (I): wherein A, B, X, Y, R1, R4 and R7 are as defined in the specification. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
Claims28
A compound of formula (I):
- or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein:
- A is a phenyl or 5- or 6-membered heteroaryl group, wherein A is substituted in the a position with B, in the β position with R7 and in the α′ position with R4, and wherein A is optionally further substituted;
- B is a phenyl, 5- or 6-membered heteroaryl, or 4- to 6-membered saturated heterocyclic group, wherein B is optionally substituted;
- X is O, NH or N(CN);
- Y is O or S;
- R1 is a C1-C4 alkyl, C2-C4 alkenyl, —NH(C1-C4 alkyl), —N(C1-C4 alkyl)2, or —R20—R21 group, all optionally halo-substituted;
- either R4 is monovalent, and attached to A in the α′ position, and selected from C1-C4 alkyl, C3-C6 cycloalkyl and phenyl, all optionally halo-substituted and/or optionally substituted with one or two substituents independently selected from oxo, —OH, —O(C1-C4 alkyl) and —O(C1-C4 haloalkyl);
- or R4 is divalent, and attached to A in the α′ and β′ positions, and selected from —CH2CH2CH2—, —CH═CHCH2—, —CH2CH═CH—, —CH2CH2O—, —OCH2CH2—, —CH2CH2CH2CH2—and —CH═CH—CH═CH—, all optionally halo-substituted and/or optionally substituted with one or two substituents independently selected from oxo, —OH, —O(C1-C4 alkyl) and —O(C1-C4 haloalkyl);
- R7 is C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, —O(C1-C4 alkyl), —O(C1-C4 haloalkyl) or halogen;
- R20 is a bond, —NH—, —NMe—, C1-C4 alkylene or C1-C4 haloalkylene;
- R21 is a C3-C6 cycloalkyl, phenyl, 4- to 6-membered saturated heterocyclic, or 5- or 6-membered heteroaryl group, all optionally halo-substituted and/or optionally substituted with one or two substituents independently selected from cyano, C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 alkenyl, C2-C4 haloalkenyl, —R22—OH, —R22—O(C1-C4 alkyl), —R22—O(C1-C4 haloalkyl), —R22—NH2, —R22—NH(C1-C4 alkyl), —R22—NH(C1-C4 haloalkyl), —R22—N(C1-C4 alkyl)2, —R22—N(C1-C4 alkyl)(C1-C4 haloalkyl), —R22—N(C1-C4 haloalkyl)2 and —R22—R23;
- R22 is a bond, C1-C4 alkylene or C1-C4 haloalkylene;
- and
- R23 is a C3-C6 cycloalkyl or 4- to 6-membered saturated heterocyclic group, all optionally halo-substituted.
11 more elements
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.